Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A novel pretargeted SPECT imaging strategy based on the HaloTag enzyme has been evaluated for the first time in a living system. To determine the efficacy of this approach, two clinically relevant cancer biomarkers, HER2 and TAG-72, were selected to represent models of internalizing and noninternalizing antigens, respectively. In MDA-MB-231/H2N (HER2-expressing) and LS174T (TAG-72-expressing) xenograft tumors in mice, pretargeting experiments were performed in which HaloTag-conjugated derivatives of the antibodies trastuzumab (anti-HER2) or CC49 (anti-TAG-72) were utilized as primary agents, and the small molecule HaloTag ligands 111In-HTL-1, -2, and -3 were evaluated as secondary agents. While this approach was not sufficiently sensitive to detect the internalizing HER2 antigen, pretargeting experiments involving the most optimal secondary agent, 111In-HTL-3, were successful in detecting the noninternalizing antigen TAG-72 and provided high-contrast SPECT images at 4 and 24 h postinjection.

Original publication

DOI

10.1021/acs.molpharmaceut.7b00172

Type

Conference paper

Publication Date

03/07/2017

Volume

14

Pages

2307 - 2313

Keywords

HaloTag, SPECT, delivery, molecular imaging, pretargeting, Animals, Antigens, Neoplasm, Cell Line, Tumor, Female, Glycoproteins, Heterografts, Humans, Indium Radioisotopes, Mice, Radioimmunotherapy, Receptor, ErbB-2, Tomography, Emission-Computed, Single-Photon